Lv2
200 积分 2024-05-30 加入
Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases
5天前
已完结
Current and Emerging Prodrug Strategies
18天前
已完结
Male premating treatment in FEED studies: Length is not everything
23天前
已完结
IL-27 signalling promotes adipocyte thermogenesis and energy expenditure
25天前
已完结
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
25天前
已完结
Lipoprotein(a)-lowering therapies: a promising future
1个月前
已完结
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor
1个月前
已完结
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
1个月前
已完结
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy
1个月前
已完结
Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study
1个月前
已完结
皖公网安备34019202002308
